ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 26, 2018, Arch Therapeutics, Inc. (the “Company”) issued a press release to provide an update for its human skin sensitization study. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.

Arch Therapeutics, Inc. Exhibit
EX-99.1 2 tv497171_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Arch Therapeutics Provides Skin Sensitization Study Status Update   Approximately two-thirds of applications in the repeat dosing induction phase are completed; Study remains on track   FRAMINGHAM,…
To view the full exhibit click here

About ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH)

Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.